Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>Novotech is the largest biotech-focused contract research organization (CRO) in the Asia-Pacific region, strategically positioned to benefit from the high-growth clinical trial market in the area.</li>
 <li>The company is pursuing an aggressive global expansion strategy, supported by significant investments from major players like TPG, GIC, and Temasek, and a series of strategic acquisitions in the US and Europe.</li>
 <li>While the company has demonstrated strong growth and has a solid backing, it operates in a highly competitive and fragmented market, and its planned IPO has been delayed, indicating potential market sensitivities.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Novotech is the largest biotech-focused contract research organization (CRO) in the Asia-Pacific region, strategically positioned to benefit from the high-growth clinical trial market in the area.
  The company is pursuing an aggressive global expansion strategy, supported by significant investments from major players like TPG, GIC, and Temasek, and a series of strategic acquisitions in the US and Europe.
  While the company has demonstrated strong growth and has a solid backing, it operates in a highly competitive and fragmented market, and its planned IPO has been delayed, indicating potential market sensitivities.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Novotech Holdings (NVT HK) - Aug 2026

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Asymchem Laboratories Tianjin / Equity Capital Markets

Asymchem Laboratories Tianjin (002821 CH)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asymchem-laboratories-tianjin-co-ltd" target="_blank" data-smartkarma-citation="entities:28265:1" rel="noopener">Asymchem Laboratories (002821 CH)</a> is a global contract development manufacturing organisation (CDMO). Asymchem is pre-marketing an H Share listing to raise $1.5 billion, according to press reports.</li>
<li>Asymchem has delivered strong growth and margin progression (on a constant currency basis) over the track record period.</li>
<li>The forward indicators suggest that the near-term prospects remain solid. Overall, we think that Asymchem has robust fundamentals.  </li>
</ul>



Asymchem Laboratories (002821 CH) is a global contract development manufacturing organisation (CDMO). Asymchem is pre-marketing an H Share listing to raise $1.5 billion, according to press reports.
Asymchem has delivered strong growth and margin progression (on a constant currency basis) over the track record period.
The forward indicators suggest that the near-term prospects remain solid. Overall, we think that Asymchem has robust fundamentals.  


Asymchem Laboratories H Share Listing: On-Demand Science

Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Novotech Holdings / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/novotech-health-holdings-ltd" target="_blank" data-smartkarma-citation="entities:33411:1" rel="noopener">Novotech Holdings (NVT HK)</a> is an Asia-Pacific biotech-focused CRO that provides clinical research services for customers from Phase I to Phase IV trials across multiple countries in the Asia-Pacific region including Greater China, South Korea and Australia/New Zealand. In our previous insight on Novotech Health’s IPO, we examined the company’s business model, revenue, margins and the outlook for the company.In this insight, we provide our forecasts for the company’s financials and what could be a potential valuation for Novotech.

Novotech Holdings (NVT HK) is an Asia-Pacific biotech-focused CRO that provides clinical research services for customers from Phase I to Phase IV trials across multiple countries in the Asia-Pacific region including Greater China, South Korea and Australia/New Zealand. In our previous insight on Novotech Health’s IPO, we examined the company’s business model, revenue, margins and the outlook for the company.In this insight, we provide our forecasts for the company’s financials and what could be a potential valuation for Novotech.

Novotech Health IPO: Forecasts, Peer Comparison and Thoughts on Valuation

<a href="https://www.smartkarma.com/entities/broncus-holding-corporation" target="_blank" data-smartkarma-citation="entities:33315:1" rel="noopener">Broncus (2216 HK)</a> is a medical device company focused on the development of interventional pulmonology products. The company has announced the terms for its IPO, where it plans to raise net proceeds of HK$1,488.1m (US$191.3m) at the midpoint of the IPO price range of HK$17.95 per share through the issuance of 89.36m (17.0% of the total outstanding shares) shares. At the midpoint of the IPO price of HK$17.95 per share, Broncus will have a market capitalisation of US$9.5bn and post-money enterprise value of HK$7.7bn.The company plans to use approx. 50.0% of the net IPO proceeds on funding its ongoing R&amp;D and planned commercial launches of its core products including InterVapor and RF-II. Broncus plans to use about 28.0% of the IPO proceeds on other products and product candidates, 13.2% of the net IPO proceeds on potential acquisitions and the remainder will be used for working capital and other general corporate purposes.Broncus also has entered into cornerstone investment agreements for an aggregate amount of US$91m (approx. HK$707m) that represents approx. 46% of the offer shares with a number of investors including UBS AM Singapore (US$25m), Lake Bleu Prime (US$20m), Snow Lake Capital (US$10m), CEPHEI (US$10m), Summer Healthcare Fund (US$10m), etc.

Broncus (2216 HK) is a medical device company focused on the development of interventional pulmonology products. The company has announced the terms for its IPO, where it plans to raise net proceeds of HK$1,488.1m (US$191.3m) at the midpoint of the IPO price range of HK$17.95 per share through the issuance of 89.36m (17.0% of the total outstanding shares) shares. At the midpoint of the IPO price of HK$17.95 per share, Broncus will have a market capitalisation of US$9.5bn and post-money enterprise value of HK$7.7bn.The company plans to use approx. 50.0% of the net IPO proceeds on funding its ongoing R&amp;D and planned commercial launches of its core products including InterVapor and RF-II. Broncus plans to use about 28.0% of the IPO proceeds on other products and product candidates, 13.2% of the net IPO proceeds on potential acquisitions and the remainder will be used for working capital and other general corporate purposes.Broncus also has entered into cornerstone investment agreements for an aggregate amount of US$91m (approx. HK$707m) that represents approx. 46% of the offer shares with a number of investors including UBS AM Singapore (US$25m), Lake Bleu Prime (US$20m), Snow Lake Capital (US$10m), CEPHEI (US$10m), Summer Healthcare Fund (US$10m), etc.

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Novotech is a leading biotech focused contract research organization in Asia Pacific. The company is looking to raise up to USD 1.5bn via a Hong Kong listing.In our previous note, we have discussed that the company has a long history of operation since 1997 and was formed by a merger of two companies. It has a customer focus on biotech companies with its flexible services, particularly services in the clinical research stage. We like the company's leading market position in Australia/New Zealand and South Korea. The company is run by a decent team and has obtained investments from a strong line-up of investors. It has been growing at a rate above the industry average but it only turned profitable in 2020. In this note, we look at the latest update of the company's operation and provide a more detailed forecast and valuation.

Novotech is a leading biotech focused contract research organization in Asia Pacific. The company is looking to raise up to USD 1.5bn via a Hong Kong listing.In our previous note, we have discussed that the company has a long history of operation since 1997 and was formed by a merger of two companies. It has a customer focus on biotech companies with its flexible services, particularly services in the clinical research stage. We like the company's leading market position in Australia/New Zealand and South Korea. The company is run by a decent team and has obtained investments from a strong line-up of investors. It has been growing at a rate above the industry average but it only turned profitable in 2020. In this note, we look at the latest update of the company's operation and provide a more detailed forecast and valuation.

Novotech Pre-IPO: PHIP and Valuation Update

China

Largest biotech specialist contract research organization (CRO) in Asia

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Novotech Holdings (NVT HK)

Primer: Novotech Holdings (NVT HK) - Aug 2026

Novotech is the largest biotech-focused contract research organization (CRO) in the Asia-Pacific region, strategically positioned to benefit...

αSK Primers

Novotech Health IPO: Forecasts, Peer Comparison and Thoughts on Valuation

Novotech Health is an Asia-Pacific biotech-focused CRO and in this insight, we provide our forecasts for the company’s financials and what could be...

Shifara Samsudeen, FCMA, CGMA

Broncus IPO Valuation: Overly Ambitious

Our reverse DCF suggests that the revenues need to grow at a CAGR of 86.3% in order to justify the implied IPO valuation of HK$7.68bn which seems...

Shifara Samsudeen, FCMA, CGMA

Novotech Pre-IPO: PHIP and Valuation Update

We look at the latest update of the Novotech's financials and operation. With new information, we provide a more detailed forecast and valuation.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Novotech Holdings (NVT HK) - Aug 2026

Novotech is the largest biotech-focused contract research organization (CRO) in the Asia-Pacific region, strategically positioned to benefit...

αSK Primers

Asymchem Laboratories H Share Listing: On-Demand Science

Asymchem is pre-marketing an H Share listing to raise $1.5 billion, according to press reports. The forward indicators suggest that the near-term...

Arun George

Novotech Health IPO: Forecasts, Peer Comparison and Thoughts on Valuation

Novotech Health is an Asia-Pacific biotech-focused CRO and in this insight, we provide our forecasts for the company’s financials and what could be...

Shifara Samsudeen, FCMA, CGMA

Broncus IPO Valuation: Overly Ambitious

Our reverse DCF suggests that the revenues need to grow at a CAGR of 86.3% in order to justify the implied IPO valuation of HK$7.68bn which seems...

Shifara Samsudeen, FCMA, CGMA

Novotech Pre-IPO: PHIP and Valuation Update

We look at the latest update of the Novotech's financials and operation. With new information, we provide a more detailed forecast and valuation.

Ke Yan, CFA, FRM